Login

Statin Intolerance

 

True statin intolerance is uncommon. Most patients can tolerate some degree of statin therapy with dose adjustment or switching.


Statins have the strongest long term evidence for reducing cardiovascular events and mortality. They should be continued if clinically approprriate, even at low or intermittent doses.


Very rarely statins can cause serious adverse affects such as rhabdomyolysis (0.1-8.4/100,000)and Autoimmune-mediated necrotizing myositis (~2/million per year)


The NHS Accelerated Access Collaborative have summarised national guidance on statin intolerance in the flow chart linked below:

 

The key insights from this guidance are below

 

Statin Related Muscle Toxicity (SRM)

  • SRM typically presents with:
    • Symmetrical pain and/or weakness in large proximal muscle groups
    • Worsened by exercise
    • Usually within 3 months of starting statins
  • There is an increased risk of SRM if:
    • Female, >75, muscular disorders, renal or hepatic impairment, hypothyroid, EtOH excess, high intensity exercise, dehydration, vitamin D deficiency
    • Specific drug interactions (see nice cks for full list of cautions and contraindications)
  • If typical symptoms then stop statin and check CK and Renal Function
    • Follow the ACC flow chart (Do not measure CK in asymptomatic patients).
  • If symptoms are atypical or occur in someone previously tolerant for >3 months, consider alternative causes

 

Rechallenge

  • Follow guidance in ACC flow chart regarding timings of rechallenge depending on CK levels, symptoms and patient preference
  • If clinically appropriate and patient willing apply a repetitive “De-Challenge” - “Re-Challenge” approach to establish if symptoms are caused by a statin(s) and the best statin regimen for each patient.
  • Consider:
    • Switching to a different statin
    • Re-challenging with the same statin using a lower dose
    • Reducing frequency e.g. alternate day or twice-weekly dosing
    • Adding ezetimibe to a lower dose statin
  • Once a new regime is tolerated statin dose / frequency can be up-titrated slowly to achieve LDL-C / non-HDL-C goals while monitoring for symptoms

 

*40mg doses of rosuvastatin should be avoided in specific patient groups: Asian ethnicity, ≥CKD 3, hereditary muscle conditions, previous muscle toxicity from lipid therapy, previous lipid therapy and alcohol misuse – see nice cks for full cautions

 

Confirmed Statin Intolerance

Treat as complete statin intolerance if:

  • Serious adverse affects or clinical concern e.g. rhabdomyolysis

AND/OR

  • No statin is tolerated at any dose or dosing frequency

AND/OR

  • Side effects or adverse events considered unacceptable to patient AND/OR


If complete statin intolerance:

  • Initiate non-statin lipid-lowering therapy e.g. ezetimibe/ bempedoic acid/ inclisiran as per primary or secondary prevention guidelines

 

Advice & Guidance

For complex or uncertain cases please submit an advice and guidance request to the lipid service

 

Referral

Emergency

  • Emergency referral to acute medicine if clinical concern for rhabdomyolysis (see AAC flow chart for CK interpretation as above)

 

Routine

  • Refer to lipid clinic for consideration of PCSK9 inhibitors (Evolocumab / Alirocumab) for very high-risk patients (e.g. familial hypercholesterolaemia) or refractory secondary prevention cases 
  • See specific criteria in primary and secondary prevention guidelines

 

Patient information

 

 

References

 

Page Review Information

Review date:           19 February 2026
Next review date:    19 February 2028
Clinical editors:        Dr Jack Munro Berry – RMS GP
Contributors:           Dr Rachel Cooper – Consultant Clinical Biochemist